Company intelligence / Profile preview

Cytogenlab

Seoul, Seoul Special City, South Koreacytogenlab.com ↗

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

Cytogen has commercialized a proprietary liquid biopsy platform that isolates viable circulating tumor cells from blood in under 30 minutes. The technology enables molecular characterization of CTCs for cancer diagnosis, patient stratification, treatment monitoring, and development of personalized therapies. The company collaborates with pharmaceutical companies and research institutes globally

Therapeutic areas: OncologyHematology
Modalities: DeviceDiagnostic technology
Industry: Molecular Diagnostics

Partnerships

Collaborations with leading domestic/global pharmaceutical companies and top-tier hospitals

Beyond the preview

Go deeper on Cytogenlab.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytogenlab.

Explore the full profile